To get the most out of this website it's best viewed on a more up-to-date browser. See how to update your browser.

Defining features of sustainable healthcare innovators

In an era of growing demand and constrained budgets, pharmaceutical innovation is not enough
01 November 2021

    In the search to treat more people at lower costs and with better outcomes, making healthcare sustainable is about looking for true value, as well as efficacy from novel molecules. This means that pharma’s innovation efforts need to be holistic, focusing on wider benefits beyond how well the treatment works – to better outcomes for the system as a whole.

    From an investment perspective, this approach does not mean inexpensive, however. “Affordability is often equated with cheap, but that’s not necessarily true,” says Dr Nathalie Flury, co-head at the Global Equity Sustainable Healthcare Fund, which aims to achieve results by focusing broadly on true innovation that helps healthcare providers and payers do more for less.

    Roche’s haemophilia drug, Hemlibra, is a good example. “It costs $500,000, which is not cheap, but is significantly more affordable than the standard therapy scheme, which costs $1.3 million,” says Flury1. The established, more expensive therapy also requires other drugs to be taken to prevent complications, whereas the Roche drug reduces bleeds by 98 per cent on its own, says Flury’s colleague Dr Michael Schröter, and her co-head at the Global Equity Sustainable Healthcare Fund. “The patient is better off, and can lead a more or less normal life.”

    Prevention is better than cure

    Prevention and early treatment also hold great promise in cutting costs while improving outcomes for patients. New colon cancer screening techniques that allow for less invasive and more regular testing are another good example of healthcare innovation that has multiple payoffs for all parties, including earlier treatment.

    Liquid biopsies for cancer patients that can detect cancer earlier, as well as track cancer progression more closely, enabling clinicians to adapt treatment paradigms accordingly, is another example of exciting new investment horizons, says Flury. “Surgeons don’t like to take traditional biopsies serially and, sometimes, this is not even possible. Everyone knows that, if you can prevent a disease developing or intervene early for a patient, it will be better, with higher survival rates – and it will be less costly for the system. These are the solutions we are searching for.”

    Other emerging diagnostic investment themes include new testing possibilities enabled by the cutting-edge sequencing of genetic material at scale and at low cost. The combination of diagnostic tools with therapies to streamline and simplify condition management is another investment theme with promise. A good example is “closed loop” diabetes treatments comprised of insulin pumps paired with continuous glucose monitoring systems that, to a great extent, automate the management of diabetes.

    These systems, which can cut a patient’s use of insulin and reduce their risk of developing diabetic complications, as well as enabling them to monitor and manage their condition better and lead fuller lives – are one example of such solutions, which offer a wide array of health, lifestyle and economic benefits and, as such, offer great potential as sustainable investment propositions.

    The future is telehealth

    Pharmaceuticals and diagnostics are not the only way to improve outcomes for patients, providers and payers. Therapies that reduce hospital stays are attractive, and telehealth is increasingly proving its considerable potential to help here. The savings can be huge. Emergency room visits, for example, can cost $10,000 per day in the US. “If you average two or three days, that’s $20,000–$30,000 saved,” says Dr Schröter.

    An emerging generation of digital monitoring solutions that enable patients to leave hospital earlier, to be monitored by care teams while recovering at home, is another promising investment proposition that has been boosted during the pandemic. It is a long-term theme, Flury believes. “I am fully persuaded that this is not going to go away when the pandemic is over,” she says. “Quite a few telemedicine companies have realised that, now their patients can be online with their physician, they will continue to use it for many things post-pandemic, such as 10-minute update. For many people, especially in the rural parts of the US, it is a huge effort to go to a doctor. This system is easier for everyone.”

    Find out more


    Key risks

    • Capital loss risk: It is important to remember that the value of investments and any income from them can go down as well as up and is not guaranteed
    • Equity risk: Funds that invest in securities listed on a stock exchange or market could be affected by general changes in the stock market. The value of investments can go down as well as up due to equity markets movements
    • Discretionary management risk: Discretionary management is based on anticipating the evolution of different markets and securities. There is a risk that the fund will not be invested at any time in the most efficient markets and securities
    • Foreign Exchange risk: Where overseas investments are held, the rate of exchange of the currency may cause the value to go down as well as up. Variations in exchange rates between currencies can have a significant impact on the performance of the products presented
    • Small & Mid cap risk: Please note that the fund is invested in securities issued by companies which, due to their small or mid-market capitalization, are less liquid and may present higher risks

    Important information

    This document is only intended for professional investors as defined by MIFID, in Switzerland by HSBC Global Asset Management (Switzerland) AG and is only intended for qualified investors in the meaning of Art. 10 para 3 of the Federal Collective Investment Schemes Act (CISA). All non-authorised reproduction or use of this commentary and analysis will be the responsibility of the user and will be likely to lead to legal proceedings. This document has no contractual value and is not by any means intended as a solicitation, nor an investment advice for the purchase or sale of any financial instrument in any jurisdiction in which such an offer is not lawful. The commentary and analysis presented in this document reflect the opinion of HSBC Asset Management on the markets, according to the information available to date. They do not constitute any kind of commitment from HSBC Global Asset Management (France). Consequently, HSBC Asset Management will not be held responsible for any investment or disinvestment decision taken on the basis of the commentary and/or analysis in this document.

    If necessary, investors can refer to the complaints handling charter available in the banner of our website.

    Please note that the distribution of the product can stop at any time by decision of the management company.

    Tax treatment depends on the individual circumstances of each client and may be subject to change in the future. Capital is not guaranteed. It is important to remember that the value of investments and any income from them can go down as well as up and is not guaranteed.

    Past performance is no guarantee of future returns. Future returns will depend inter alia on market developments, the fund manager’s skill, the fund’s level risk and management costs and if applicable subscription and redemption costs. The return, the value of money invested in the fund may become negative as a result of price losses and currency fluctuations. There is no guarantee that all of your invested capital can be redeemed. Unless stated otherwise, inflation is not taken into account.

    Synthetic Risk and Reward Indicator (SRRI): 6 out of 7. Do not run any unnecessary risk. Read the Key Investor Information Document. The fund invests in instruments of high level of volatility. The value of investments can go up as well as down. The rating is based on price volatility over the last five years, and is an indicator of absolute risk. Historical data may not be a reliable indication for the future. The scale varies from 1 (least risky) to 7 (most risky). The rating is not guaranteed to remain unchanged and the categorisation may shift over time. The lowest rating does not mean a risk-free investment. Do not run any unnecessary risk. Read the Key Investor Information Document.

    Important information for Luxembourg investors: HSBC entities in Luxembourg are regulated and authorised by the Commission de Surveillance du Secteur Financier (CSSF).

    Important information for Swiss investors: This document may be distributed in Switzerland only to qualified investors according to Art. 10 para 3, 3bis and 3ter CISA. The presented fund is authorised for distribution in Switzerland in the meaning of Art. 120 CISA. (Potential) investors are kindly asked to consult the latest issued Key Investor Information Document (KIID), prospectus, articles of incorporation and the (semi-)annual report of the fund which may be obtained free of charge at the head office of the representative: HSBC Global Asset Management (Switzerland) AG, Gartenstrasse26, P.O. Box, CH-8002 Zurich. Paying agent in Switzerland: HSBC Private Bank (Suisse) SA, Quai des Bergues9-17, P.O Box 2888, CH-1211 Genève 1.

    HSBC GIF Global Equity Sustainable Healthcare is a sub fund of HSBC Global Investment Funds, a Luxemburg domiciled SICAV. Before subscription, investors should refer to Key Investor Document (KIID) of the fund as well as its complete prospectus. For more detailed information on the risks associated with this fund, investors should refer to the complete prospectus of the fund. The shares of HSBC Global Investment Funds have not been and will not be offered for sale or sold in the United States of America, its territories or possessions and all areas subject to its jurisdiction, or to United States Persons.

    Any forecast, projection or target where provided is indicative only and is not guaranteed in any way.

    Allocation is as at the date indicated, may not represent current or future allocation and is subject to change without prior notice.

    These examples are historical and contains information that is not current and should not be construed as an advice, an offer to sell or solicitation of an offer to purchase or subscribe to any investment.

    Swing pricing and Gates: Yes.

    “Swing pricing” is a price adjustment mechanism intended to protect the unitholders, or shareholders, of a collective investment undertaking (UCI) against the transaction costs borne by this UCI due to new subscriptions or new buyouts. These transaction costs include, but are not limited to, broker commissions (for equities), the spread between the bid and ask prices (for interest rate products), taxes on financial transactions, fees transactions taken by the depositary, etc.

    The fund has a redemption threshold (gate), the level at which the manager of an undertaking for collective investment in transferable securities can stagger the redemption of securities instead of proceeding immediately.

    Article 8 SFDR =The product promotes environmental or social characteristics, or a combination of those characteristics, provided that the companies in which the investments are made follow good governance practices  even if this is not its central point, or the central point of the investment process.

    More information on our ‘Responsible Investment’ Policy and ‘Implementation Procedures’ can be found on our website. The decision to invest in the promoted fund should take into account all the characteristics or objectives of the promoted fund as described in its prospectus.

    HSBC Asset Management is the brand name for the asset management business of HSBC Group. The above document has been produced by HSBC Global Asset Management (France) and has been approved for distribution/issue by the following entities:

    HSBC Global Asset Management (France) - 421 345 489 RCS Nanterre. Portfolio management company authorised by the French regulatory authority AMF (no. GP99026) with capital of 8.050.320 euros, in Italy, Spain and Sweden through the Milan, Madrid and Stockholm branches of HSBC Global Asset Management (France), regulated respectively by Banca d’Italia and Commissione Nazionale per le Società e la Borsa (Consob) in Italy, the Comisión Nacional del Mercado de Valores (CNMV) in Spain and the Swedish Financial Supervisory Authority (Finansinspektionen) in Sweden. Offices: HSBC Global Asset Management (France)

    Immeuble Coeur Défense - 110, esplanade du Général Charles de Gaulle - 92400 Courbevoie - La Défense 4 – France.
    (Website: www.assetmanagement.hsbc.com/fr).

    HSBC Global Asset Management (Switzerland) AG: Gartenstrasse 26, P.O. Box, CH-8002 Zurich. Paying agent: HSBC Private Bank (Suisse) S.A., Quai des Bergues 9-17, P. O. Box 2888, CH-1211 Geneva 1 In respect of the units distributed in Switzerland, the competent courts shall have exclusive venue at the registered office of the Representative in Switzerland. The official documents as per Art. 13a CISO as well as the (Semi-)Annual Report of the Fund may be obtained free of charge at the office of the Representative in Switzerland.
    (Website: www.assetmanagement.hsbc.com/ch)

    Non contractual document
    Copyright : All rights reserved ©  HSBC Global Asset Management (France), 2021.